Header Logo

Connection

Alan Go to Warfarin

Back to Details
This is a "connection" page, showing publications Alan Go has written about Warfarin.
Alan Go
Connection Strength
6.489
Warfarin
  1. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism. JAMA Netw Open. 2023 08 01; 6(8):e2328033.
    View in: PubMed
    Score: 0.873
  2. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding. J Thromb Thrombolysis. 2022 Oct; 54(3):470-479.
    View in: PubMed
    Score: 0.817
  3. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017 Dec 19; 167(12):845-854.
    View in: PubMed
    Score: 0.588
  4. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009 Sep 01; 151(5):297-305.
    View in: PubMed
    Score: 0.333
  5. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009 Jul; 2(4):297-304.
    View in: PubMed
    Score: 0.328
  6. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008; 22(10):815-25.
    View in: PubMed
    Score: 0.296
  7. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92.
    View in: PubMed
    Score: 0.223
  8. Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism. Thromb Res. 2022 Aug; 216:97-102.
    View in: PubMed
    Score: 0.202
  9. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000 Jul 04; 102(1):11-3.
    View in: PubMed
    Score: 0.176
  10. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020 08; 226:85-93.
    View in: PubMed
    Score: 0.174
  11. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 Dec 21; 131(12):927-34.
    View in: PubMed
    Score: 0.170
  12. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439.
    View in: PubMed
    Score: 0.157
  13. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc. 2017 01; 65(1):35-41.
    View in: PubMed
    Score: 0.137
  14. Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Heart Assoc. 2016 07 22; 5(7).
    View in: PubMed
    Score: 0.134
  15. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation? Am J Cardiol. 2016 09 01; 118(5):697-9.
    View in: PubMed
    Score: 0.133
  16. Anticoagulation in atrial fibrillation: impact of mental illness. Am J Manag Care. 2015 Nov 01; 21(11):e609-17.
    View in: PubMed
    Score: 0.128
  17. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul; 170(1):141-8, 148.e1.
    View in: PubMed
    Score: 0.122
  18. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015 Jan 01; 115(1):40-6.
    View in: PubMed
    Score: 0.119
  19. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014 Aug 15; 114(4):583-6.
    View in: PubMed
    Score: 0.116
  20. Mental illness and warfarin use in atrial fibrillation. Am J Manag Care. 2011 Sep; 17(9):617-24.
    View in: PubMed
    Score: 0.096
  21. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul 19; 58(4):395-401.
    View in: PubMed
    Score: 0.095
  22. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011 Jan 04; 154(1):1-11.
    View in: PubMed
    Score: 0.090
  23. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 Nov; 3(6):624-31.
    View in: PubMed
    Score: 0.090
  24. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med. 2009 Nov 23; 169(21):2032; author reply 2033.
    View in: PubMed
    Score: 0.085
  25. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 Mar 17; 119(10):1363-9.
    View in: PubMed
    Score: 0.080
  26. The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research. Circ Cardiovasc Qual Outcomes. 2008 Nov; 1(2):138-47.
    View in: PubMed
    Score: 0.079
  27. Stroke prevention in atrial fibrillation: another step sideways. Lancet. 2008 Jan 26; 371(9609):278-80.
    View in: PubMed
    Score: 0.074
  28. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 Aug; 120(8):700-5.
    View in: PubMed
    Score: 0.071
  29. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006 Aug; 54(8):1231-6.
    View in: PubMed
    Score: 0.067
  30. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep 20; 112(12):1687-91.
    View in: PubMed
    Score: 0.063
  31. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 Nov 16; 141(10):745-52.
    View in: PubMed
    Score: 0.060
  32. The importance of anticoagulation management services. Manag Care. 2004 Sep; 13(9 Suppl):20-5.
    View in: PubMed
    Score: 0.059
  33. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11; 349(11):1019-26.
    View in: PubMed
    Score: 0.055
  34. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001 Sep 18; 135(6):393-400.
    View in: PubMed
    Score: 0.048
  35. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. Am Heart J. 2019 07; 213:81-90.
    View in: PubMed
    Score: 0.041
  36. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol. 2016 06; 9(6).
    View in: PubMed
    Score: 0.033
  37. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 06; 129(6):592-599.e1.
    View in: PubMed
    Score: 0.032
  38. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013 Jan 15; 127(2):224-32.
    View in: PubMed
    Score: 0.026
  39. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):546S-592S.
    View in: PubMed
    Score: 0.019

© 2024 Kaiser Permanente